Treatment arm continues to demonstrate favorable relapse-free survival (HR=0.50; p=0.23) and overall survival (HR=0.61; p=0.52) 3/3 (100%) of TSC-101-treated patients who reached two-year follow-up ...

Late-breaking HERIZON-GEA-01 presentation highlights the expanding clinical profile of Ziihera across HER2-driven gastrointestinal cancersJazz to host ...

The climate crisis is no longer a distant threat — it’s happening now. Floods, wildfires, droughts, and record-breaking heat ...

From San Rafael to the communities of El Alacrán, more than 2,500 families remain there, where erosion has reduced the width ...

From missile silos to high-end hypogeal complexes, how underground shelters are becoming a new infrastructure of privilege, ...

OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / ...

LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the ...

Q3 2025 Earnings Call Transcript November 13, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.19, expectations were $-0.58. Operator: Thank you for your patience. Today’s ...

Jennifer Spinghart does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

This is not the way they want to go viral. Clout-seeking travel influencers are doing more than just displaying their ignorance abroad — they could be endangering people’s lives. A charity has warned ...

NEW YORK, Oct. 13, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of ...